<?xml version="1.0" encoding="UTF-8"?>
<clinical_study>
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 09, 2025</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT00075374</url>
  </required_header>
  <id_info>
    <org_study_id>MSMC1503</org_study_id>
    <secondary_id>CWRU-MSMC-1503</secondary_id>
    <secondary_id>AVENTIS-GIA-12143</secondary_id>
    <secondary_id>THERADEX-GIA-12143</secondary_id>
    <secondary_id>MTSMC-LUN06</secondary_id>
    <nct_id>NCT00075374</nct_id>
  </id_info>
  <brief_title>Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Multicenter, Randomized Phase II Study of Two Schedules of Taxotere (Weekly Versus Every 3 Weeks) in Elderly or Poor Performance (ECOG PS 2), Chemotherapy-Naive Patients With Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>RATIONALE: Drugs used in chemotherapy, such as docetaxel, use different ways to stop&#xd;
tumor cells from dividing so they stop growing or die. It is not yet known which&#xd;
docetaxel regimen is more effective for non-small cell lung cancer.&#xd;
&#xd;
PURPOSE: Randomized phase II trial to compare the effectiveness of two regimens of&#xd;
docetaxel in treating patients who have not previously received chemotherapy for&#xd;
unresectable stage IIIB or stage IV non-small cell lung cancer.</textblock>
  </brief_summary>
  <detailed_description>
    <textblock>OBJECTIVES:&#xd;
&#xd;
Primary&#xd;
&#xd;
  -  Compare the effects of two different schedules of docetaxel on the incidence of&#xd;
     grade 3 and 4 toxic effects in older or poor performance chemotherapy-na√Øve patients&#xd;
     with unresectable stage IIIB or IV non-small cell lung cancer.&#xd;
&#xd;
Secondary&#xd;
&#xd;
  -  Compare the overall survival of patients treated with these regimens.&#xd;
&#xd;
  -  Compare the response rate in patients treated with these regimens.&#xd;
&#xd;
  -  Compare the incidence of serious adverse events in patients treated with these&#xd;
     regimens.&#xd;
&#xd;
  -  Determine the quality of life of patients treated with these regimens.&#xd;
&#xd;
OUTLINE: This is an open-label, randomized, multicenter study. Patients are randomized to&#xd;
1 of 2 treatment arms.&#xd;
&#xd;
  -  Arm I: Patients receive docetaxel IV over 1 hour on day 1. Treatment repeats every&#xd;
     21 days in the absence of disease progression or unacceptable toxicity.&#xd;
&#xd;
  -  Arm II: Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15.&#xd;
     Treatment repeats every 28 days in the absence of disease progression or&#xd;
     unacceptable toxicity.&#xd;
&#xd;
Quality of life is assessed at baseline, every 2 courses during study treatment, and then&#xd;
at study completion.&#xd;
&#xd;
Patients are followed at 1 month and then every 2-3 months thereafter.&#xd;
&#xd;
PROJECTED ACCRUAL: A total of 210-230 patients (105-115 per treatment arm) will be&#xd;
accrued for this study.</textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Patients receive docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in&#xd;
the absence of disease progression or unacceptable toxicity.&#xd;
&#xd;
OR Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats&#xd;
every 28 days in the absence of disease progression or unacceptable toxicity.&#xd;
&#xd;
Quality of life is assessed at baseline, every 2 courses during study treatment, and then&#xd;
at study completion.&#xd;
&#xd;
Patients are followed at 1 month and then every 2-3 months thereafter.</description>
    <arm_group_label>Docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
    <other_name>Docefrez</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>DISEASE CHARACTERISTICS:&#xd;
&#xd;
  -  Histologically or cytologically confirmed non-small cell lung cancer&#xd;
&#xd;
       -  Unresectable stage IIIB or IV disease&#xd;
&#xd;
  -  No untreated brain or leptomeningeal metastases&#xd;
&#xd;
       -  Treated patients must be neurologically stable and the adverse effects from&#xd;
          prior therapy must be resolved to grade 2 or less after the completion of&#xd;
          treatment&#xd;
&#xd;
  -  No symptomatic (i.e., requiring thoracentesis) pleural effusion&#xd;
&#xd;
  -  No clinically significant (i.e., grade 3 or greater) pericardial effusion&#xd;
&#xd;
PATIENT CHARACTERISTICS:&#xd;
&#xd;
Age&#xd;
&#xd;
  -  18 and over&#xd;
&#xd;
Performance status&#xd;
&#xd;
  -  ECOG 0-2 (70 years of age and over) OR&#xd;
&#xd;
  -  ECOG 2 (under 70 years of age)&#xd;
&#xd;
Life expectancy&#xd;
&#xd;
  -  Not specified&#xd;
&#xd;
Hematopoietic&#xd;
&#xd;
  -  Absolute neutrophil count at least 1,500/mm^3&#xd;
&#xd;
  -  Platelet count at least 100,000/mm^3&#xd;
&#xd;
  -  Hemoglobin at least 8.0 g/dL&#xd;
&#xd;
Hepatic&#xd;
&#xd;
  -  Bilirubin normal&#xd;
&#xd;
  -  AST and ALT no greater than 2.5 times upper limit of normal (ULN) if alkaline&#xd;
     phosphatase is no greater than ULN OR&#xd;
&#xd;
  -  Alkaline phosphatase no greater than 4 times ULN if ALT and AST are no greater than&#xd;
     ULN&#xd;
&#xd;
Renal&#xd;
&#xd;
  -  Not specified&#xd;
&#xd;
Other&#xd;
&#xd;
  -  Not pregnant or nursing&#xd;
&#xd;
  -  Negative pregnancy test&#xd;
&#xd;
  -  Fertile patients must use effective contraception during and for 6 months after&#xd;
     study participation&#xd;
&#xd;
  -  No grade 2 or greater peripheral neuropathy&#xd;
&#xd;
  -  No prior hypersensitivity reaction to taxanes or products containing polysorbate 80&#xd;
&#xd;
  -  No other active malignancy except carcinoma in situ of the cervix or basal cell skin&#xd;
     cancer&#xd;
&#xd;
  -  No psychological, familial, sociological, or geographical condition that would&#xd;
     preclude study treatment or follow-up&#xd;
&#xd;
PRIOR CONCURRENT THERAPY:&#xd;
&#xd;
Biologic therapy&#xd;
&#xd;
  -  Not specified&#xd;
&#xd;
Chemotherapy&#xd;
&#xd;
  -  No prior chemotherapy&#xd;
&#xd;
Endocrine therapy&#xd;
&#xd;
  -  Not specified&#xd;
&#xd;
Radiotherapy&#xd;
&#xd;
  -  Recovered from prior radiotherapy (i.e., side effects resolved to grade 2 or less)&#xd;
&#xd;
  -  No concurrent radiotherapy&#xd;
&#xd;
Surgery&#xd;
&#xd;
  -  More than 3 weeks since prior major surgery&#xd;
&#xd;
Other&#xd;
&#xd;
  -  More than 30 days since prior anticancer investigational drugs&#xd;
&#xd;
       -  Concurrent supportive care investigational agents allowed</textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Afshin Dowlati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>January 9, 2004</study_first_submitted>
  <study_first_submitted_qc>January 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2004</study_first_posted>
  <last_update_submitted>January 15, 2014</last_update_submitted>
  <last_update_submitted_qc>January 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
</clinical_study>
